B. Riley raised the firm’s price target on CymaBay to $29 from $22 and keeps a Buy rating on the shares after the company submitted its NDA for seladelpar in PBC and requested a Priority Review. Seladelpar is “positioned well for best-in-indication market penetration that could help improve investor perception,” the analyst contends.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CBAY: